Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

IMVT-1402 Misses Primary Endpoint in Cutaneous Lupus Proof-of-Concept Trial

24 September 2026 · By · Wire by Fusion42

Published

24 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at clinicaltrialvanguard.com →

◆ Verified

Fusion42 · 24 September 2026 · Fusion42 review

IMVT-1402 failed to show statistically significant improvement in cutaneous lupus erythematosus in a proof-of-concept trial, leading Immunovant to discontinue development for this indication, though other programs remain unaffected.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your drug targeting IgG autoantibodies faces new doubts after the trial failure in lupus skin disease. Focus on exploring patient subgroups or alternative autoimmune conditions where FcRn inhibitors have clearer impact.

◆ Coverage

1 source · 24 Sep 2026

◆ Related on Wire

◆ Topics

Biotechclinical-trialimmunovantcutaneous-lupusfcrn-inhibitordrug-development